Johnson & Johnson (NYSE:JNJ) — Market Cap & Net Worth
Market Cap & Net Worth: Johnson & Johnson (JNJ)
Johnson & Johnson (NYSE:JNJ) has a market capitalization of $547.37 Billion ($547.37 Billion) as of May 3, 2026. Listed on the NYSE stock exchange, this USA-based company holds position #23 globally and #17 in its home market, demonstrating a -1.50% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Johnson & Johnson's stock price $227.19 by its total outstanding shares 2409295102 (2.41 Billion). Analyse Johnson & Johnson cash flow conversion to see how efficiently the company converts income to cash.
Johnson & Johnson Market Cap History: 2015 to 2026
Johnson & Johnson's market capitalization history from 2015 to 2026. Data shows growth from $193.36 Billion to $547.37 Billion (10.95% CAGR).
Index Memberships
Johnson & Johnson is a constituent of 6 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
Dow Jones Composite Average
DJA
|
$16.47 Trillion | 3.32% | #7 of 65 |
|
DJC: Dow Jones-UBS Commodity Index
DJC
|
$23.29 Trillion | 1.52% | #8 of 65 |
|
Dow Jones Industrial Average
DJI
|
$21.53 Trillion | 2.31% | #8 of 30 |
|
ARCA Pharmaceutical
DRG
|
$3.19 Trillion | 17.17% | #2 of 24 |
|
S&P 500 Index
GSPC
|
$59.46 Trillion | 0.80% | #16 of 503 |
|
S&P 100
OEX
|
$42.94 Trillion | 1.14% | #16 of 101 |
Weight: Johnson & Johnson's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Johnson & Johnson Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Johnson & Johnson's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
5.29x
Johnson & Johnson's market cap is 5.29 times its annual revenue
Latest Price to Earnings (P/E) Ratio
18.60x
Johnson & Johnson's market cap is 18.60 times its annual earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2016 | $223.00 Billion | $71.89 Billion | $16.54 Billion | 3.10x | 13.48x |
| 2017 | $277.47 Billion | $76.45 Billion | $1.30 Billion | 3.63x | 213.44x |
| 2018 | $263.23 Billion | $81.58 Billion | $15.30 Billion | 3.23x | 17.21x |
| 2019 | $305.93 Billion | $82.06 Billion | $15.12 Billion | 3.73x | 20.23x |
| 2020 | $339.04 Billion | $82.58 Billion | $14.71 Billion | 4.11x | 23.04x |
| 2021 | $377.82 Billion | $78.74 Billion | $20.88 Billion | 4.80x | 18.10x |
| 2022 | $400.39 Billion | $79.99 Billion | $17.94 Billion | 5.01x | 22.32x |
| 2023 | $366.04 Billion | $85.16 Billion | $35.15 Billion | 4.30x | 10.41x |
| 2024 | $348.43 Billion | $88.82 Billion | $14.07 Billion | 3.92x | 24.77x |
| 2025 | $498.60 Billion | $94.19 Billion | $26.80 Billion | 5.29x | 18.60x |
Competitor Companies of JNJ by Market Capitalization
Companies near Johnson & Johnson in the global market cap rankings as of May 3, 2026.
Key companies related to Johnson & Johnson by market ranking:
- Eli Lilly and Company (NYSE:LLY): Ranked #16 globally with a market cap of $862.20 Billion USD.
- Eli Lilly and Company (SA:LILY34): Ranked #17 globally with a market cap of $853.51 Billion USD ( R$4.35 Trillion BRL).
- AbbVie Inc (NYSE:ABBV): Ranked #37 globally with a market cap of $365.30 Billion USD.
- AstraZeneca PLC (MX:AZNN): Ranked #52 globally with a market cap of $290.50 Billion USD ( MX$5.05 Trillion MXN).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #16 | Eli Lilly and Company | NYSE:LLY | $862.20 Billion | $963.33 |
| #17 | Eli Lilly and Company | SA:LILY34 | $853.51 Billion | R$153.70 |
| #37 | AbbVie Inc | NYSE:ABBV | $365.30 Billion | $206.60 |
| #52 | AstraZeneca PLC | MX:AZNN | $290.50 Billion | MX$1628.00 |
Johnson & Johnson Historical Marketcap From 2015 to 2026
Between 2015 and today, Johnson & Johnson's market cap moved from $193.36 Billion to $ 547.37 Billion, with a yearly change of 10.95%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $547.37 Billion | +9.78% |
| 2025 | $498.60 Billion | +43.10% |
| 2024 | $348.43 Billion | -4.81% |
| 2023 | $366.04 Billion | -8.58% |
| 2022 | $400.39 Billion | +5.97% |
| 2021 | $377.82 Billion | +11.44% |
| 2020 | $339.04 Billion | +10.82% |
| 2019 | $305.93 Billion | +16.22% |
| 2018 | $263.23 Billion | -5.13% |
| 2017 | $277.47 Billion | +24.43% |
| 2016 | $223.00 Billion | +15.33% |
| 2015 | $193.36 Billion | -- |
End of Day Market Cap According to Different Sources
On May 2nd, 2026 the market cap of Johnson & Johnson was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $547.37 Billion USD |
| MoneyControl | $547.37 Billion USD |
| MarketWatch | $547.37 Billion USD |
| marketcap.company | $547.37 Billion USD |
| Reuters | $547.37 Billion USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Johnson & Johnson
Johnson & Johnson, together with its subsidiaries, engages in the research and development, manufacture, and sale of various products in the healthcare field worldwide. It operates in two segments, Innovative Medicine and MedTech. The Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bow… Read more